Fig. 4

Comparison of the SRRM with TMB score and PD-L1 expression. A Images with negative (left) and positive (right) PD-L1 expression on immunohistochemistry are shown. B Different frequencies of immunotherapy among SRRM-low, PD-L1-high expression, and TMB-low groups. C ROC curves of predictive immunotherapy response using the SRRM, PD-L1 expression, and TMB score in the training and D validation cohorts. PD-L1 programmed death-ligand 1, TMB tumor mutational burden, SRRM sub-regional radiomics model, ROC receiver operating characteristic